Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial by CNBC Markets | February 3, 2026 6:20 pm | US Markets The data on Pfizer’s GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
